Effect observation of Yiqi Yangyin Tongluo Recipein the treatment of patients with diabetic nephropathy in stage Ⅲ to Ⅳ differentiated as syndrome of deficiency of qi and yin complicated with blood stasis

TANG Chenquan; ZHOU Enchao

doi:10.7619/jcmp.20201463

Journal of Clinical Medicine in Practice > 2021 > 25(5): 79-82. > DOI: 10.7619/jcmp.20201463

TANG Chenquan, ZHOU Enchao. Effect observation of Yiqi Yangyin Tongluo Recipein the treatment of patients with diabetic nephropathy in stage Ⅲ to Ⅳ differentiated as syndrome of deficiency of qi and yin complicated with blood stasis[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 79-82. DOI: 10.7619/jcmp.20201463

Citation:

PDF (582 KB)

Effect observation of Yiqi Yangyin Tongluo Recipein the treatment of patients with diabetic nephropathy in stage Ⅲ to Ⅳ differentiated as syndrome of deficiency of qi and yin complicated with blood stasis

TANG Chenquan,
ZHOU Enchao^,

Department of Nephrology, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu, 210029

More Information

Received Date: November 15, 2020
Available Online: March 22, 2021
Published Date: March 14, 2021

Graphical Abstract

Abstract

Abstract

Objective To observe the clinical efficacy of Yiqi Yangyin Tongluo Recipe in the treatment of patients with diabetic nephropathy (DN) in stage Ⅲ to Ⅳ differentiated as syndrome of deficiency of qi and yin complicated with blood stasis.
Methods Totally 80 patients with DN in stage Ⅲ to Ⅳ differentiated as syndrome of deficiency of qi and yin complicated with blood stasis were randomly divided into control group and observation group, with 40 cases in each group. Both groups were conducted with conventional treatment, the control group was treated with benazepril, and the observation group was treated with Yiqi Yangyin Tongluo Recipe. The TCM syndrome score, clinical efficacy, serum creatinine, urea nitrogen, 24 h urinary protein quantification, microalbuminuria, ratio of microalbuminuria to creatinine (ACR), serum tumor necrosis factor-α (TNF-α) and C reactive protein (CRP) were compared between the two groups before and after treatment.
Results After treatment, the TCM syndrome score of the observation group was (11.90±2.30) points, which was significantly lower than (16.70±6.30) points of the control group (P < 0.05). The total effective rate was 82.50% in the observation group, which was significantly higher than 40.00% in the control group (P < 0.05). After treatment, levels of 24 h urinary protein quantification, microalbuminuria, ACR, serum creatinine and urea nitrogen in the observation group were significantly lower than those in the control group (P < 0.05). After treatment, CRP and TNF-α in both groups were lower than those before treatment, and the CRP and TNF-α in the observation group were significantly lower than the control group (P < 0.05). There were no obvious adverse reactions during treatment in both groups.
Conclusion Yiqi Yangyin Tongluo Recipe can significantly improve the symptoms and signs of DN patients, reduce proteinuria, improve renal function, delay the progression of DN, and has no obvious adverse reactions.

FullText(HTML)

References (21)

References

[1]	ZHANG L X, LONG J Y, JIANG W S, et al. Trends in chronic kidney disease in China[J]. N Engl J Med, 2016, 375(9): 905-906. doi: 10.1056/NEJMc1602469
[2]	IWAI T, MIYAZAKI M, YAMADA G, et al. Diabetes mellitus as a cause or comorbidity of chronic kidney disease and its outcomes: the Gonryo study[J]. Clin Exp Nephrol, 2018, 22(2): 328-336. doi: 10.1007/s10157-017-1451-4
[3]	黄力, 葛永纯. 免疫炎症与糖尿病肾病[J]. 肾脏病与透析肾移植杂志, 2019, 28(3): 247-251. https://www.cnki.com.cn/Article/CJFDTOTAL-SZBY201903013.htm
[4]	中华医学会糖尿病学分会微血管并发症学组. 糖尿病肾病防治专家共识(2014年版)[J]. 中华糖尿病杂志, 2014, 6(11): 792-801. doi: 10.3760/cma.j.issn.1674-5809.2014.11.004
[5]	MOGENSEN C E, CHRISTENSEN C K, VITTINGHUS E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy[J]. Diabetes, 1983, 32(Suppl 2): 64-78. http://ndt.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=diabetes&resid=32/Supplement_2/64
[6]	郑筱萸. 中药新药临床研究指导原则(试行)[M]. 北京: 中国医药科技出版社, 2002: 1-41.
[7]	丁小强, 朱加明. 糖尿病肾病诊治的研究进展、存在问题与展望[J]. 上海医学, 2018, 41(2): 73-77. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYX201802004.htm
[8]	XU K, GUO L, BU H, et al. Daphnetin inhibits high glucose-induced extracellular matrix accumulation, oxidative stress and inflammation in human glomerular mesangial cells[J]. J Pharmacol Sci, 2019, 139(2): 91-97. doi: 10.1016/j.jphs.2018.11.013
[9]	严倩华, 盛梅笑, 余江毅, 等. 芪葵颗粒对早期糖尿病肾病患者微量白蛋白尿及病情进展的影响[J]. 中国中西医结合杂志, 2018, 38(4): 430-434. https://www.cnki.com.cn/Article/CJFDTOTAL-ZZXJ201804012.htm
[10]	朱蓓, 宋卫国, 彭璘. 糖尿病肾病微炎症及氧化应激的中医药研究进展[J]. 江西中医药, 2016, 47(7): 72-74. https://www.cnki.com.cn/Article/CJFDTOTAL-JXZY201607031.htm
[11]	GE C X, XU M X, QIN Y T, et al. Fisetin supplementation prevents high fat diet-induced diabetic nephropathy by repressing insulin resistance and RIP₃-regulated inflammation[J]. Food Funct, 2019, 10(5): 2970-2985. doi: 10.1039/C8FO01653D
[12]	朱丽坤, 曹爽, 蒋仕林, 等. 黄芪注射液对db/db小鼠肾脏IL-1β、MCP-1和TNF-α的mRNA表达的影响[J]. 实验动物与比较医学, 2020, 40(1): 60-64. https://www.cnki.com.cn/Article/CJFDTOTAL-SHSY202001010.htm
[13]	周恩超. 邹燕勤中医肾病学术经验传承与创新[M]. 南京: 江苏科学技术出版社, 2014: 31-33.
[14]	蔡然, 崔建华. 黄芪注射液对早期糖尿病肾病患者尿白蛋白及细胞因子的影响[J]. 现代中西医结合杂志, 2016, 25(28): 3117-3119. doi: 10.3969/j.issn.1008-8849.2016.28.012
[15]	杨柳, 李爱平, 张王宁, 等. 黄芪及含黄芪经方在治疗肾病方面的药理作用及临床应用研究进展[J]. 中草药, 2018, 49(14): 3419-3424. doi: 10.7501/j.issn.0253-2670.2018.14.031
[16]	姜梦真, 任惠娟, 徐蕾, 等. 黄芪、水蛭有效成分对大鼠肾小球系膜细胞凋亡的影响[J]. 中成药, 2017, 39(5): 902-906. https://www.cnki.com.cn/Article/CJFDTOTAL-ZCYA201705004.htm
[17]	杜珍芳, 黄敏, 张慧, 等. 益气养阴通络方治疗糖尿病肾病3期气阴亏虚夹瘀型患者的疗效观察[J]. 实用临床医药杂志, 2019, 23(15): 79-82. doi: 10.7619/jcmp.201915021
[18]	王琳. 自拟黄芪参七汤治疗糖尿病肾病的效果及对患者血清miRNA-21和NF-κB表达的影响[J]. 中国实用医刊, 2019, 46(15): 109-113. http://d.wanfangdata.com.cn/periodical/zyyk201915037
[19]	陈国宁, 卞海林. 依帕司他联合黄芪注射液对糖尿病肾病患者疗效和血液流变学的影响[J]. 实用临床医药杂志, 2011, 15(21): 100-101. doi: 10.3969/j.issn.1672-2353.2011.21.039
[20]	张子力, 董慧. 水蛭及其有效成分治疗糖尿病肾脏病的研究进展[J]. 中西医结合研究, 2018, 10(2): 106-110. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYH201802023.htm
[21]	曲波. 黄蛭合剂治疗糖尿病肾病的临床研究[J]. 中国当代医药, 2012, 19(4): 59, 61. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGUD201204033.htm

Cited By

Cited by

Periodical cited type(8)

1.	赵莉，马居里，刘金响，曹文斌，袁秀丽，秦刚新，苏衍进. 益气通络类中药复方联合西药治疗糖尿病肾病的有效性与安全性的Meta分析. 中国医院用药评价与分析. 2025(02): 188-193 .
2.	王桂勤，刘迎见，李冉. 滋肾益气消瘀汤联合西药对老年气阴两虚兼血瘀型糖尿病肾病病人Galectin-3、Nesfatin-1水平的影响. 中西医结合心脑血管病杂志. 2024(01): 164-167 .
3.	陈仕银，胡朋. 益气养阴通络汤联合贝那普利治疗糖尿病肾病疗效及对血清TGF-β1、VEGF指标影响. 中华中医药学刊. 2024(03): 238-242 .
4.	罗珍莲，宋子豪，孙伟，赵静. 中医药治疗糖尿病肾病蛋白尿研究进展. 广西中医药. 2024(05): 70-73 .
5.	李凤，郭力，蔡利群. 益气养阴通络方联合羟苯磺酸钙对气阴两虚血瘀证糖尿病肾病疗效的影响. 实用临床医药杂志. 2023(15): 40-44 . 本站查看
6.	韩世辉，丁勇旗. 益气养阴合清热利湿法治疗糖尿病肾病蛋白尿患者临床疗效及对血清炎性因子、肾功能的影响. 湖北中医杂志. 2023(12): 6-8 .
7.	杜新国，于新. 益气养阴消癥通络中药治疗早期糖尿病肾病的临床研究. 中国卫生标准管理. 2022(17): 158-162 .
8.	方熙声，江璇. 参芪麦味地黄汤联合中药灌肠治疗糖尿病早、中期肾病临床疗效分析. 中外医疗. 2022(17): 21-25 .

Other cited types(2)

Get Citation

PDF

XML

Article views (330) PDF downloads (9) Cited by(10)

Turn off MathJax

Article Contents

Abstract

References

Effect observation of Yiqi Yangyin Tongluo Recipein the treatment of patients with diabetic nephropathy in stage Ⅲ to Ⅳ differentiated as syndrome of deficiency of qi and yin complicated with blood stasis

Abstract

References

Cited by

Periodical cited type(8)

Other cited types(2)

Catalog

Export File

Citation

Format

Content